Open AccessSGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
Author(s) -
Henith Raj,
Harsh Durgia,
Rajan Palui,
Sadishkumar Kamalanathan,
Sandhiya Selvarajan,
Sitanshu Sekhar Kar,
Jayaprakash Sahoo
Publication year - 2019
Publication title -
world journal of diabetes
Language(s) - English
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v10.i2.114
Subject(s) - medicine , fatty liver , type 2 diabetes , diabetes mellitus , gastroenterology , steatohepatitis , cochrane library , dapagliflozin , adverse effect , clinical trial , meta analysis , disease , endocrinology
Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity with type 2 diabetes. The existing therapeutic options for NAFLD are not adequate. Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD. Pioglitazone is the only drug recommended in diabetes patients with biopsy proven non-alcoholic steatohepatitis. The frequent coexistence of NAFLD and type 2 diabetes with their combined adverse health consequences and inadequate therapeutic options makes it necessary to search for newer alternatives.